




FULL-LENGTH ORIGINAL RESEARCH**Design and implementation of electronic health record common data elements for pediatric epilepsy: Foundations for a learning health care system**

Zachary M. Grinspan¹  | **Anup D. Patel²**  | **Renée A. Shellhaas³**  | **Anne T. Berg^{4,5}**  | **Erika T. Axeen⁶** | **Jeffrey Bolton^{7,8}** | **David F. Clarke⁹** | **Jason Coryell¹⁰** | **William D. Gaillard¹¹**  | **Howard P. Goodkin⁶** | **Sookyong Koh¹²**  | **Alison Kukla¹³** | **Juma S. Mbwana¹¹** | **Lindsey A. Morgan^{14,15}** | **Nilika S. Singhal¹⁶** | **Margaret M. Storey¹⁷** | **Elissa G. Yozowitz¹⁸**  | **Nicholas S. Abend^{19,20}**  | **Mark P. Fitzgerald^{19,20}**  | **Sara E. Fridinger^{19,20}** | **Ingo Helbig^{19,20,21,22}** | **Shavonne L. Massey^{19,20}** | **Marisa S. Prelack^{19,20}** | **Jeffrey Buchhalter²³**  | **the Pediatric Epilepsy Learning Healthcare System**

¹Departments of Population Health Sciences and Pediatrics, Weill Cornell Medicine, New York, NY, USA

²Division of Neurology, Nationwide Children's Hospital, Columbus, OH, USA

³Department of Pediatrics (Pediatric Neurology), Michigan Medicine, University of Michigan, Ann Arbor, MI, USA

⁴Division of Neurology, Epilepsy Center, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA

⁵Department of Pediatrics, Northwestern Feinberg School of Medicine, Chicago, IL, USA

⁶Department of Neurology, University of Virginia, Charlottesville, VA, USA

⁷Harvard Medical School, Boston, MA, USA

⁸Division of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital, Boston, MA, USA

⁹Division of Pediatric Neurology, Department of Neurology, Dell Medical School, University of Texas at Austin, Austin, TX, USA

¹⁰Departments of Pediatrics and Neurology, Oregon Health and Sciences University, Portland, OR, USA

¹¹Department of Neurology, Children's National Health System and School of Medicine, George Washington University, Washington, DC, USA

¹²Department of Pediatrics, Emory Children's Center, Emory University School of Medicine, Atlanta, GA, USA

¹³Epilepsy Foundation, Landover, MD, USA

¹⁴Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA, USA

¹⁵Departments of Pediatrics and Neurology, Seattle Children's Hospital, University of Washington, Washington, DC, USA

¹⁶Departments of Neurology and Pediatrics, UCSF Benioff Children's Hospital, University of California, San Francisco, CA, USA

¹⁷Department of History, College of Liberal Arts and Social Sciences, DePaul University, Chicago, IL, USA

¹⁸Saul Korey Department of Neurology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY, USA

¹⁹Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, PA, USA

²⁰Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

²¹Epilepsy NeuroGenetics Initiative, Children's Hospital of Philadelphia, Philadelphia, PA, USA

²²Department of Biomedical and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, PA, USA

²³Department of Neurology, St Joseph's Hospital and Medical Center, Phoenix, AZ, USA

Correspondence

Zachary Grinspan, Department of Population Health Sciences, Weill Cornell Medicine, 402 E 67th Street, New York, NY 10065, USA.
Email: zag9005@med.cornell.edu

Funding information

The authors gratefully acknowledge the support of this project from the BAND Foundation, Pediatric Epilepsy Research Foundation, and Epilepsy Foundation

Abstract

Objective: Common data elements (CDEs) are standardized questions and answer choices that allow aggregation, analysis, and comparison of observations from multiple sources. Clinical CDEs are foundational for learning health care systems, a data-driven approach to health care focused on continuous improvement of outcomes. We aimed to create clinical CDEs for pediatric epilepsy.

Methods: A multiple stakeholder group (clinicians, researchers, parents, caregivers, advocates, and electronic health record [EHR] vendors) developed clinical CDEs for routine care of children with epilepsy. Initial drafts drew from clinical epilepsy note templates, CDEs created for clinical research, items in existing registries, consensus documents and guidelines, quality metrics, and outcomes needed for demonstration projects. The CDEs were refined through discussion and field testing. We describe the development process, rationale for CDE selection, findings from piloting, and the CDEs themselves. We also describe early implementation, including experience with EHR systems and compatibility with the International League Against Epilepsy classification of seizure types.

Results: Common data elements were drafted in August 2017 and finalized in January 2020. Prioritized outcomes included seizure control, seizure freedom, American Academy of Neurology quality measures, presence of common comorbidities, and quality of life. The CDEs were piloted at 224 visits at 10 centers. The final CDEs included 36 questions in nine sections (number of questions): diagnosis (1), seizure frequency (9), quality of life (2), epilepsy history (6), etiology (8), comorbidities (2), treatment (2), process measures (5), and longitudinal history notes (1). Seizures are categorized as generalized tonic-clonic (regardless of onset), motor, nonmotor, and epileptic spasms. Focality is collected as epilepsy type rather than seizure type. Seizure frequency is measured in nine levels (all used during piloting). The CDEs were implemented in three vendor systems. Early clinical adoption included 1294 encounters at one center.

Significance: We created, piloted, refined, finalized, and implemented a novel set of clinical CDEs for pediatric epilepsy.

KEYWORDS

common data elements, electronic health records, epilepsy, informatics, pediatrics

1 | INTRODUCTION

A learning health care system is an approach to care delivery that encourages continuous improvement of clinical outcomes through cycles of data aggregation, analysis, reporting, and change in clinical practice, in partnership with patients and caregivers.¹ For a learning health care system to succeed, standardized clinical data must be collected through routine care processes. A foundational step is to specify common data elements (CDEs). CDEs are standardized questions and answer choices that allow aggregation, analysis, and comparison of observations from multiple sources.

As an example of epilepsy CDEs, the National Institute of Neurological Diseases and Stroke (NINDS) convened experts to create a repository of standardized clinical case

report forms and validated scales for epilepsy clinical investigation.² The NINDS CDEs, however, were designed for a clinical research context, where dedicated research staff complete comprehensive assessments outside of standard clinical workflows. In contrast, clinical CDEs must facilitate rapid, efficient data collection in a potentially busy clinical practice, while also supporting billing requirements, quality improvement initiatives, and easy access to important data at subsequent clinical encounters. Furthermore, for CDEs to fully support learning health care systems, patients and caregivers must participate in development.

As part of our effort to build a pediatric epilepsy learning health care system, we developed CDEs that were relevant for patient care, usable to measure preidentified quality improvement priorities, and compatible with the workflow

demands of routine clinical encounters. People with epilepsy and caregivers were integral members of the research team throughout.

2 | MATERIALS AND METHODS

We conducted an iterative series of mixed methods exercises to develop CDEs for pediatric epilepsy. Some activities included human subjects, which were described in a central institutional review board protocol (Biomedical Research Alliance of New York) and approved by participating sites. Participating clinical sites were members of the Pediatric Epilepsy Learning Healthcare System (PELHS), a project affiliated with the Pediatric Epilepsy Research Consortium.³

We began with five parallel activities conducted with a multidisciplinary group including pediatric epilepsy clinicians, clinical researchers, epidemiologists, parents of children with epilepsy, people with epilepsy, and leaders of epilepsy advocacy organizations (Appendix 1, Figure 1).

We collected and reviewed existing documents with standardized clinical data, including (1) clinical notes and templates from multiple pediatric epilepsy centers; (2) existing sources of CDEs for clinical research (NINDS epilepsy CDEs)²; and (3) data dictionaries of three active USA-based multicenter registries: the Early Life Epilepsy Study database⁴ (which included the National Infantile Spasms Consortium database⁵), the Neonatal Seizure Registry,⁶ and the Pediatric Status Epilepticus Research Group.⁷ These were reviewed by one reviewer (Z.M.G.) and used as preparatory material for group discussions.

Six group discussions were convened to identify important outcomes for children with epilepsy (each group with multiple stakeholders). In the first three group discussions, participants generated a list of important outcomes, then ranked their top three choices. In the second three group discussions,

Key Points

- Clinical CDEs are standardized questions and answers to allow observations from multiple sources to be compared
- CDEs are foundational for learning health care systems, a data-driven approach to health care focused on continuous improvement of outcomes
- A multiple stakeholder group created, piloted, finalized, and implemented pediatric epilepsy clinical CDEs
- Seizures are categorized into four groups, focality is collected via epilepsy type, and seizure frequency is measured in nine levels
- Successful piloting at 10 centers (224 visits) and implementation at one center (1294 visits) are favorable for broad adoption and use

participants named published articles that changed clinical practice. The outcomes reported in these publications were manually extracted by one investigator (Z.M.G.) and added to the list of outcomes generated in the first three groups (Table 1).

We also identified outcomes for five PELHS demonstration projects (planned prior to the CDE development process; ongoing). These five include three field tests of American Academy of Neurology/Child Neurology Society (AAN/CNS) quality measures^{8,9} and two projects to compare the effectiveness of treatments for neonatal encephalopathy and new onset focal epilepsy.

Next, one investigator (Z.M.G.) drafted question and answer choices (CDEs) designed to adhere closely to existing




FIGURE 1 Consensus Process to create and disseminate Pediatric Epilepsy Learning Health System registry questions for use at the point of care. CDE, common data elements; EHR, electronic health record; ELES, Early Life Epilepsy Study; NINDS, National Institute of Neurological Disorders and Stroke; NISC, National Infantile Spasms Consortium; NSR, Neonatal Seizure Registry; pSERG, Pediatric Status Epilepticus Group

TABLE 1 Pediatric epilepsy outcomes and key references

Category	Outcome	Measurable by clinical CDEs developed in this study?
Seizure control, Seizure freedom	Seizure free for 1 mo, 6 mo, 1 y, 2 y ⁵³	Yes
	No generalized tonic-clonic seizures ¹⁹	Yes
	No status epilepticus ¹⁹	Yes
	Reduction in frequency by 50% ^{54,55}	Approximate; categorical seizure frequency question
	Ordinal outcomes ⁵⁶	Approximate; would require development of computable phenotype
	Freedom from treatment failure ⁵⁷	Yes
	5 y remission ⁵⁶	If multiple visits (longest interval in questions is 2 y)
Infantile spasms	Resolution of clinical spasms by 2 wk ⁵	Yes
	Sustained resolution of spasms at 3 mo ⁵	Yes
	No infantile spasms from day 14 to day 42 ⁵⁸	Approximate; answer choices for spasms allow detection of 2 wk & 1 mo freedom from spasms
	Resolution of clinical spasms <i>and</i> hypsarrhythmia ⁵⁹	No; EEG standard forms in development
Quality measures	Met AAN epilepsy / child neurology quality measures ^{8,9,60}	Yes
	Discussed SUDEP? ⁶¹	Yes
Other key outcomes	Presence of common comorbidities ⁶²	Yes
	Obtain genetic testing ⁶	Yes
	Quality of life ^{26,63}	Yes (novel instrument, undergoing validation)
	Development ⁶⁴	Approximate; clinical impression not standard measures
	Sleep ⁶⁵	Presence/absence of sleep disorder
	Use of health services ⁶⁶	No
	Costs ⁶⁷	No
	Medication side effects ²⁷	Indirectly; quality of life instrument measures how side effects affect daily routines
	Patient-reported outcomes ⁶⁸	No
	Adherence ⁶⁹	No
	Full-scale IQ ⁷⁰	No
	Social (education, stigma, driving) ⁷¹	No
	Burden on family ⁷²	No
	Patient/family engagement ⁷³	No
	Successful transition ⁷⁴	No
Access to care ⁷⁵	No	

^aAbbreviations: AAN, American Academy of Neurology; CDE, common data element; EEG, electroencephalographic; IQ, intelligence quotient; SUDEP, sudden unexpected death in epilepsy.

data elements, measure outcomes prioritized in the group discussions, and support the five demonstration projects. This draft was disseminated via email to PELHS participants for comment and iteratively refined, based on feedback from email, discussions at four PELHS in-person meetings (December 2017 to May 2018), and weekly PELHS operational calls December 2017 to November 2018. Concurrently, we consulted with electronic health record (EHR) vendors¹⁰ and institutional operational health information technology teams (Appendix 1) for guidance on implementation.

The refined draft was piloted at 10 centers (on paper). Centers were selected from PELHS participants based on

clinician volunteers. Participating clinicians completed the pilot CDEs during or after outpatient clinical encounters. The pilot CDEs did not include demographic information (which is collected by administrative staff, not clinicians). Responses were deidentified for analysis. Qualitative observations from clinicians were gathered via email, verbal feedback on teleconferences, and in-person discussions. Several clinicians provided feedback from patients and caregivers, and some reported the length of time required to fill out the form. The CDEs were refined based on this feedback.

The consensus CDEs were submitted to three EHR vendors for evaluation prior to implementation (Epic Systems

Corporation, Verona, WI; Cerner Corporation, North Kansas City, MO; Athenahealth Inc, Watertown, MA). The CDEs were again modified.

We report themes that emerged in discussion groups, in-person meetings, phone calls, and email exchanges, using a modified thematic analysis approach.¹¹ We did not assess thematic saturation.

We present the final set of CDEs, including a description of the survey logic, and the rationale for each question. We indicate which CDEs “copy forward,” that is, persist from one clinical encounter to the next without requiring data re-entry. We were attentive to the associated risks (ie, failure to update important information) and benefits (ie, avoiding errors and saving time for entry of complex information that does not change frequently) associated with copy and paste functions in EHR notes.¹² We provide screen shots of implemented CDEs.

We provide additional detail about seizure documentation. First, the CDEs include seizure frequency response categories based on review of previous seizure frequency scales,¹³ subsequently revised by multistakeholder input and piloting. We describe these categories and report preliminary frequencies for levels of the scale from the pilot (10 centers) and from clinical use at one center (Children's Hospital of Philadelphia). Second, the CDEs track seizures in categories that are less specific than the seizure categories endorsed by the International League Against Epilepsy (ILAE); we demonstrate the relationship between these systems with a conceptual map.¹⁴

Statistical analyses were performed with R (R Foundation).

3 | RESULTS

We examined clinical notes and templates from 11 academic pediatric epilepsy programs (of 18 centers participating in phone calls). Clinicians at three of these 11 centers also dictate notes as free text.

Each discussion group included three to eight individuals (Appendix 1). The prioritization process (first three groups) indicated improved seizure control was the single most important data element. Other highly prioritized outcomes included presence of comorbidities (psychiatric/behavioral/developmental), medication side effects, health services outcomes (ie, emergency department visits), and quality of life/burden on family. Table 1 describes all discussed outcomes.

Seizure frequency items ask about the time since the last seizure, then the frequency of that seizure type. Frequency is measured in nine levels: too many to count, multiple per day, daily, weekly but not daily, monthly but not weekly, at least once per year but not every month, less than once per year, uncertain, and frequency not well defined. “Too many to count” was requested by parents because “multiple per day”

did not adequately capture their experience. “Uncertain” and “frequency not well defined” were requested by clinicians, to distinguish between “insufficient information to characterize seizure frequency” and “frequency of seizures not well captured by other choices (eg, seizure clusters).”

Piloting occurred at 224 visits at 10 academic pediatric epilepsy centers. Most patients had established epilepsy (95%). Common characteristics included treatment resistance (42%), developmental delay (72%), and unknown etiology (61%). Thirty percent had abnormal brain imaging related to epilepsy. Forty percent had undergone genetic testing, some with an identified genetic cause (17% of responses, 40% of those with testing). Epilepsy type was largely known (93%), with good representation of focal (38%), generalized (34%), and mixed (22%). Age at onset ranged from neonatal to adult. Some had a history of epilepsy surgery (12%), and a few had metabolic (2%), infectious (2%), and autoimmune (1.4%) etiologies (Table S1). For most questions, there were one to five missing replies (ie, 0.4%-2.2%). There were more missing replies for epilepsy type (11% missing) and genetic testing (17%).

During piloting, 322 responses used the seizure frequency scale at 215 of the 224 visits (nine visits with no seizure categories, 104 with multiple seizure categories). This included 122 children with generalized tonic-clonic seizures (GTCs), 123 motor seizures, and 77 nonmotor seizures. All nine choices were selected at least 12 times (ranging from 12 for “too many to count” to 81 for “less than once per year”; Figure 2) The seizure frequency scale was implemented and used at one center for 887 children (47% female) at 1294 visits (median age at visit = 8.0 years, interquartile range = 4-12 years, range = 39 days to 37 years), including 375 visits with children with GTCs, 621 motor seizures, 397 nonmotor seizures, and 58 epileptic spasms. The option “frequency not well defined” was not included in the implementation. All eight remaining choices were used (ranging from 18 (1.4% of visits) for “uncertain” to 340 (26% of visits) for “at least once per year but not every month”).

Qualitative feedback from in-person meetings, phone calls, and emails indicated poor consensus about the number of questions and answer choices. Arguments favoring more were to (1) improve granularity of data collected, particularly about seizure types; (2) provide exhaustive lists of abnormalities; (3) adhere closely to the ILAE seizure and epilepsy classification^{14,15}; and (4) increase the number of measurable outcomes. Arguments favoring fewer were to (1) emphasize outcomes over historical details, (2) consolidate ILAE concepts into fewer answer choices, (3) limit the cognitive burden of multiple mouse clicks,¹⁶ and (4) allow rapid completion of the questions (clinicians often said “<2 minutes” was acceptable).

Feedback from piloting led to multiple changes. For example, because epilepsy type was often missing due to lack




FIGURE 2 Responses to questions during the pilot (blue; 10 centers) and implementation (orange; one center) about the most recent seizure (top row) and the overall frequency of seizures (bottom row) for four seizure types (columns). For infantile spasms, treatment response is all-or-none; thus, frequency of epileptic spasms is not collected. Of note, three labels at the implementation site were slightly different than in the pilot: (1) “too many to count” was labeled “many per day”; (2) “multiple per day” was labeled “several per day”; and (3) “frequency not well defined” was not included as a response. GTC, generalized tonic-clonic

of clinical certainty, we added clarifying text: “best guess, taking into consideration history and diagnostic findings.” The final CDEs are summarized in Table 2 (see Appendix 2 for full text).

Diagnosis (one question; copies forward) asks if the child has epilepsy. The 2014 ILAE operational definition of epilepsy is provided as guidance.¹⁷ This question excludes children with single seizures and low risk of recurrence, febrile only seizures, or events that are uncertain to be seizures.

Seizure frequency (nine questions; does not copy forward) asks about five seizure types: GTCs (regardless of focal or generalized onset), motor seizures that are not GTCs, nonmotor seizures, epileptic spasms, and status epilepticus. For GTCs, motor seizures, and nonmotor seizures, the clinician first indicates when the most recent seizure occurred. If it was within 6 months, the clinician then selects the overall frequency. For GTCs, clinicians indicate whether seizures occur at night or from sleep. The question on status epilepticus asks whether any episodes occurred in the past 12 months. The question on epileptic spasms only asks when was the last spasm (ie, not the frequency), and only appears for children younger than 3 years old. In selecting these nine questions, the following considerations were discussed.

First, the form simplifies the 25+ ILAE¹⁴ seizure types into four (Figure 3). GTCs are a well-established risk factor for sudden unexpected death,¹⁸ and families prioritize reducing this seizure type.¹⁹ Motor seizures are counted more reliably than nonmotor seizures.^{20,21} Tracking epileptic spasms in infants supports quality improvement initiatives and comparative effectiveness research.^{9,22} Epileptic spasms in older children are classified as

motor seizures. The question text includes guidance classifying seizures (Appendix 2).

Second, occurrence of status epilepticus is separately assessed. Prior episodes predict future episodes,²³ most recurrences happen within 1 year,²³ and there are interventions that can reduce risk (ie, home rescue benzodiazepines²⁴).

Third, localization is captured with *epilepsy type* rather than *seizure type*.^{14,15} Epilepsy type (focal, generalized, both, or unknown) supports medication selection and identification of surgical candidacy. Seizure type (focal onset, generalized onset, or unknown) helps determine epilepsy type, and can be described in free text.

Fourth, some ILAE concepts are not captured. The effect on awareness, for example, can be described in free text. “Unclassified” seizures are categorized based on the presence of movement.

Quality of life (two questions; does not copy forward) asks two novel quality of life questions about the effect of seizures and antiseizure medication (ASM) side effects on routines. These questions have been validated²⁵ and correlate with known scales, such as Quality of Life in Childhood Epilepsy Questionnaire–55²⁶ and Pediatric Epilepsy Side Effects Questionnaire.²⁷

Epilepsy history (six questions; copies forward) asks about epilepsy type (focal, generalized, both, or unknown), treatment resistance, recency of onset, age at first unprovoked seizure, current epilepsy syndrome, and specific conditions associated with epilepsy (eg, Aicardi or Angelman syndromes). Clinicians requested questions on prior epilepsy surgery, but they were removed by EHR vendors to consolidate questions on surgical history elsewhere.

TABLE 2 Common data elements for pediatric epilepsy, for use at the point of care

Section	Question ^a	Notes
Diagnosis	Has epilepsy? (CF)	ILAE operational definition provided as reference
Seizure frequency	Last generalized tonic-clonic seizure	
	<i>Frequency of GTCs</i>	If any GTCs
	<i>Any GTCs at night?</i>	If any GTCs
	Last motor seizure	
	<i>Frequency of motor seizures</i>	If any motor seizures
	Last nonmotor seizure	
	<i>Frequency of nonmotor seizures</i>	If any nonmotor seizures
	<i>Last[†] epileptic spasm</i>	If age < 3 y
Quality of life	Seizure effect on routines	These two novel questions are undergoing validation; manuscript in preparation
	ASM effect on routines	
Epilepsy history	Epilepsy type (CF)	Focal, generalized, both, unknown
	Intractable? (CF)	
	New onset? (CF)	
	Age at onset? (CF)	
	Current epilepsy syndrome (CF)	
	Specific conditions (CF)	Aicardi, Angelman, etc
Epilepsy etiology	Etiology known? (CF)	
	Abnormal brain imaging? (CF)	
	<i>Detail on brain imaging (CF)</i>	If abnormality
	Known genetic etiology? (CF)	
	<i>Detail on genetics (CF)</i>	If known genetics
	Metabolic etiology? (CF)	
	Infectious etiology? (CF)	
	Autoimmune etiology? (CF)	
Comorbidities	Developmental delay? (CF)	Based on clinical impression, not formal testing

TABLE 2 (Continued)

Section	Question ^a	Notes
	Selected comorbidities present? (CF)	Psychiatric, behavioral, cognitive, neurologic, head size, and technology dependence
Treatment	Ketogenic diet? Refer to epilepsy surgery conference?	
Process measures	Discussed SUDEP?	
	<i>Discussed transitions?</i>	Age ≥ 13 y
	<i>Psych comorbidity screened for?</i>	Age ≥ 7 y
	<i>Pregnancy/contraception counseling?</i>	Age ≥ 12 y & female
	<i>Infantile spasms—1st line therapy?</i>	If infantile spasms
Longitudinal history notes	Free text (CF)	Optional—for other aspects of the history that are likely to persist from visit to visit

Note: CF indicates that the data persist and autopopulate subsequent notes.

Abbreviations: ASM, antiseizure medication; CF, copy forward; GTC, generalized tonic-clonic seizure; ILAE, International League Against Epilepsy; SUDEP, sudden unexpected death in epilepsy.

^aItalics if conditional.

[†]Response to treatment for infantile spasms is all-or-none. Thus the frequency of epileptic spasms is not tracked.

Epilepsy etiology (eight questions; copies forward) asks whether the etiology is known, about findings from brain imaging and genetic testing, and whether metabolic, infectious, or autoimmune etiologies are present. Detailed subquestions about imaging and genetics appear if the abnormalities explain the reason for epilepsy. The list of imaging findings was modified from work examining findings in children with infantile spasms.²⁸ Genetic and chromosomal etiologies were selected to capture abnormalities responsible for at least 1% of epilepsies with a known genetic etiology.²⁹

Comorbidities (two questions; copies forward) asks about development and common comorbidities. Clinicians are encouraged to assess development based on a standard neurological history and examination without further formal testing. Comorbidities include common psychiatric, behavioral, cognitive, and neurologic conditions (including sleep disorders), as well as abnormal head size and technology dependence.

Treatments (two questions; does not copy forward) covers dietary therapy and referral for epilepsy surgery evaluation. Clinicians had requested an extensive list of medical and surgical treatments as part of the CDEs themselves; however, EHR

(Continues)




FIGURE 3 Relationship between Pediatric Epilepsy Learning Healthcare System (PELHS) seizure outcomes and the International League Against Epilepsy (ILAE) seizure classification system (Fisher et al¹⁴). Seizure types are in general mapped to three concepts: generalized tonic-clonic seizures, regardless of onset (black lines, gray box), motor seizures (blue), and nonmotor seizures (orange). For children younger than 3 years, epileptic spasms are tracked separately (green). Aware versus impaired awareness is not explicitly captured. Unclassified seizures are categorized based on presence/absence of movement

vendors noted that medications are documented elsewhere in the chart, and adding CDEs for medications would (1) introduce redundancies, (2) become outdated as new medications became available, and (3) potentially introduce medical errors by bypassing systems for review of allergies and drug-drug interactions.

Process measures (five questions; does not copy forward) includes questions related to four AAN/CNS quality measures (transition to adult care, screening for mental health comorbidities, counseling about contraception and/or pregnancy, and first-line therapy for infantile spasms)^{8,9} and one measure requested by families and advocacy groups (sudden unexpected death in epilepsy counseling, an AAN Guideline).³⁰ Each question appears only for target populations.

Epilepsy longitudinal history note (one question; copies forward) provides free text for information that might persist from visit to visit, such as additional relevant history, a running list of previously tried ASMs, or detailed electroencephalographic (EEG) or magnetic resonance imaging findings. EHR vendors and information technology experts advised avoiding the term “continuity of care” for this item, to avoid confusion with text fields elsewhere in the EHR.

This set of questions, when linked with EHR data like visit history, demographics, medication administration, and prescription data, tracks many but not all of the outcomes listed by the discussion groups (Table 1). The questions have

been implemented in three EHR vendor systems (Figure 4). The specifications (Table 2 and Appendix 2) were largely followed, with minor changes.

4 | DISCUSSION

4.1 | Summary of findings

We designed, iterated, piloted, finalized, and implemented clinical CDEs for routine care of children with epilepsy, with multistakeholder input, including clinicians, researchers, parents and caregivers, advocates, and EHR vendors. The CDEs include two novel quality of life questions²⁵ and a categorical seizure frequency scale with nine levels. Each seizure frequency level was selected during piloting and clinical use, without requests by users for additional answer choices, suggesting the scale is sufficiently granular for clinical use. The CDEs have been implemented by three EHR vendors.

4.2 | Learning health care systems

The CDEs were designed to support a pediatric epilepsy learning health care system, in which clinical data are collected,

aggregated across multiple sites, analyzed, and returned to centers to support quality improvement, comparative effectiveness research, surveillance and epidemiology, health services research, and direct improvements in clinical care and patient outcomes.¹ This approach to health care delivery has dramatically improved health outcomes for children with other pediatric diseases, notably cancer,³¹ inflammatory bowel disease,³² and hypoplastic left heart syndrome.³³ The success of the CDEs will depend on adoption and use, which in turn will depend on how well they support efficient clinical workflow.

4.3 | Involvement of patients and caregivers

We included, from the beginning, people with epilepsy, caregivers, and advocacy group leaders to align with the principles of patient-centered care and patient-centered research (ie, the ethos of “nothing about me without me”^{34,35}). Multiple suggestions from nonclinician participants were adopted, such as

inclusion of quality of life questions and the addition of a “too many to count” option for seizure frequency. We anticipate multistakeholder involvement will improve adoption.

4.4 | Epilepsy and EHR tools

Several ongoing efforts have customized EHR systems to support care of people with epilepsy.³⁶ For example, a practice in Ireland described the sociotechnical environment of clinical epilepsy documentation at their center,³⁷ followed by design and implementation of a custom-built system,³⁸ and subsequent upgrades to include clinical genetics evaluations.³⁹ An epilepsy practice in the USA created and implemented a tool for detailed data collection for use in a well-staffed outpatient practice.⁴⁰ One vendor (Epic Systems Corporation, Verona, WI) hosts neuroscience specialty steering boards (pediatric and adult), which successfully created multiple tools for neurologists’ use in clinical care, including for epilepsy.¹⁰ Our work builds upon and expands these efforts.

A Last GENERALIZED TONIC CLONIC Seizure (including clonic-tonic-clonic, myoclonic-tonic-clonic, and focal onset seizures with secondary generalization)

Never/does not have this seizure type	Today	1-6 days ago (up to 1 week)
1-4 weeks ago (up to 1 month)	5-12 weeks ago (1 to 3 months)	13-26 weeks ago (3 to 6 months)
6-12 months ago	13-24 months ago	More than 2 years ago
Uncertain		

B Tonic-clonic timeframe of last seizure

today	1-6 days ago	1-4 weeks ago	5-12 weeks ago
13-26 weeks ago	6-12 months ago	13-24 months ago	more than 2 years ago
unknown			

C Last GENERALIZED TONIC CLONIC Seizure (Including clonic-tonic-clonic, myoclonic-tonic-clonic, and focal onset seizures with secondary generalization)

<input type="radio"/> Never/Does not have this seizure type	<input type="radio"/> 5-12 weeks ago (1 to 3 months)
<input type="radio"/> Uncertain	<input type="radio"/> 13-26 weeks ago (3 to 6 months)
<input type="radio"/> Today	<input type="radio"/> 6-12 months ago
<input type="radio"/> 1-6 days ago (up to 1 week)	<input type="radio"/> 13-24 months ago
<input type="radio"/> 1-4 weeks ago (up to 1 month)	<input type="radio"/> More than 2 years ago

D Last generalized tonic clonic seizure

never/does not have this seizure type	today	1-6 days ago (up to 1 week)
1-4 weeks ago (up to month)	5/12 weeks ago (1 to 3 months)	
13-26 weeks ago (3 to 6 months)	6-12 months ago	13-24 months ago
more than 2 years ago	uncertain	

FIGURE 4 Examples of the Pediatric Epilepsy Learning Healthcare System question about the last generalized tonic-clonic seizure, as implemented in three electronic health record systems at four centers. A, B, Epic Systems Corporation (Verona, WI). C, Cerner Corporation (North Kansas City, MO). D, Athenahealth Inc (Watertown, MA). The question and answers are conceptually identical; however, there are variations in interface (buttons vs radio boxes), wording, capitalization, and the order of answer choices. In one implementation (B), the question appears only if the patient is known to have tonic-clonic seizures, and so there is no option “Never/does not have this seizure type”

4.5 | Expectation for use

The CDEs are not comprehensive. Clinicians will need to separately document the history of present illness, past medical and surgical history, physical examination, results from laboratory and diagnostic studies, medical decision-making, and orders. This is by design, to preserve rich narrative detail not easily captured in standardized fields. We found that some clinicians dictate these narrative sections; they may continue to do so. The CDEs were designed for in-person office visits, but may also be used for phone calls, telehealth visits, or inpatient encounters.

4.6 | Benefits and risks of data standardization

Adoption and use of well-designed clinical CDEs have the potential to allow a clinician to document an epilepsy evaluation without prolonging the office visit. In addition, clinical CDEs reduce variation within EHRs; these variations increase the time required for clinicians to find key clinical data, which may lead to patient harm.⁴¹ Standardized data can also power decision support, that is, the automated delivery of targeted information to help clinical decision-making at the point of care. CDEs can also support reporting for management and quality improvement initiatives, for example, to identify patients with treatment-resistant epilepsy for referral to surgical management. Finally, CDEs can support clinical research, in that they capture important clinical characteristics and outcomes through routine care processes, avoiding double entry into research databases.⁴²

There are risks, however. Clicking through standardized answer choices may limit free text narrative, which often contains rich, humanizing, and clinically important details.⁴³ Increasing standardization of data entry can increase time spent on documentation, at the expense of time for direct patient care.⁴⁴ Furthermore, poorly designed health information technology can contribute to physician burnout.⁴⁵ For example, cognitive burden of data entry into an EHR form can be measured in computer mouse clicks,⁴⁶ and our clinical CDEs will add clicks to each patient encounter. Successful implementation of the CDEs must include careful attention to clinician workflow, to minimize these and other potential negative consequences of standardization.

4.7 | Clinical CDEs versus other CDEs

The NINDS epilepsy CDEs were designed for research settings, whereas clinical CDEs are designed for clinical workflow, and thus prioritize ease-of-use over granularity to encourage adoption. For example, the clinical CDEs do not capture details of individual seizures, whereas the

NINDS CDEs support documentation of multiple specific seizure types. In the clinical CDEs, epilepsy etiology is determined using a more-likely-than-not standard, whereas in the NINDS CDEs confidence is graded along the spectrum possible-probable-definite. The NINDS CDEs include etiologies important in adult epilepsy (eg, dementia) that are not included in the pediatric-focused clinical CDEs. The clinical CDEs ask for a broad assessment of development (normal, mild delay, definite delay in one domain, definite delay in two or three domains), whereas the NINDS CDEs include multiple detailed validated instruments of development across several domains. Clinical CDEs should also be distinguished from CDEs for devices,⁴⁷ which provide detailed specifications for software developers.

4.8 | Potential pitfalls

Impactful health information technology must support interactions among clinicians, health care organizations, and the technology itself.⁴⁸ Recognition of four potential pitfalls will help ongoing implementation and dissemination of the CDEs.

First, the current answer choices will need revision over time, as conceptualization and knowledge of epilepsy evolve. For example, the list of important genetic etiologies and understanding of the pathogenicity of specific mutations will likely grow. As an interim solution, the current CDEs allow users to specify any mutation as free text. However, future versions may need to revise the choices. Of importance, to interpret genetic findings, clinicians should refer to vendor reports or centralized repositories such as the ClinGen Epilepsy Gene Curation Panel.⁴⁹

Second, variations in implementation (see Figure 4) demonstrate that user experience will differ from center to center. Dissemination of the CDEs centrally may help reduce these variations.¹⁰

Third, poor consensus about the number of questions indicates that some will find the CDEs too long, and others insufficiently detailed. Efforts to improve adoption might emphasize a core set of CDEs (ie, the seizure frequency questions), leave other CDEs as optional, and allow sites to develop supplementary CDEs.

Fourth, frequently missing replies about epilepsy type (11% missing) and genetic testing (17% missing) and qualitative feedback suggest these questions require more thought by clinicians than the other CDEs. Determining epilepsy type requires synthesis of the neurologic history, seizure types, and diagnostic data. Understanding genetic testing history often requires searching through the chart for testing results. Quality improvement initiatives (such as encouraging use of the “longitudinal history” element) may help clinicians with these questions.

4.9 | Limitations

Several limitations merit discussion.

First, the clinical CDEs are closely aligned with the ILAE framework for seizures, epilepsies,^{14,15} and epilepsy syndromes,⁵⁰ but the overlap is not exact. For example, some epilepsy syndromes have been merged into a single category (eg, Benign Occipital Epilepsy combines Panayiotopoulos Syndrome and Idiopathic Childhood Occipital Epilepsy of Gastaut) and others are not explicitly listed (eg, absence epilepsy with eyelid myoclonia). We note, however, that the ILAE framework is a working consensus that generated robust debate, and will continue to evolve.⁵¹

Second, input was almost exclusively from participants within the USA. Our choices may not capture variations across international practice.

Third, several important outcomes are not well captured, including EEG outcomes, burden on family, adherence, transition of care from pediatric to adult clinicians, social outcomes, and access to care. Linking these outcomes to data collected through the CDEs will require additional standardization work (for EEG), care delivery innovations (such as devices or integration of patient-reported outcomes), and/or linkage with other datasets (health insurance claims data or social determinants of health databases). In addition, medication side effects are measured only broadly—sufficient for a global estimate without detailed tracking of specific side effects.⁵²

Fourth, our discussion and consensus methodology prioritized iterative development over traditional qualitative methods, such as focus groups, Delphi processes, or interviews. This process may have introduced biases, in that we did not explicitly guard against outsized influence from vocal participants.

Fifth, differences in workflow across different EHRs may lead to differences in cognitive burden of data entry. This may affect adoption across institutions, biasing data collected from the CDEs toward centers with EHRs that more efficiently support clinical workflow.

Sixth, although most of the CDEs have fixed answer choices, there are several free text fields. Gathering usable data from these fields will require manual review or natural language processing techniques.

Finally, the CDEs were designed for general use for children with epilepsy, and may not include details tracked in specialized programs, such as for specific causes of epilepsy (ie, renal angiomyolipomas for tuberous sclerosis) or for surgical evaluation. Development of CDEs in these contexts would require additional input from relevant stakeholders (ie, advocacy groups, neurosurgeons, etc).

4.10 | Conclusions and next steps

The CDEs have the potential to improve clinical care and support projects in quality improvement, surveillance and epidemiology, comparative effectiveness research, and health services research. Future work is needed to understand adoption, use, potential negative side effects, and sustainability of the CDEs.

CONFLICT OF INTEREST

Z.M.G. has received research support from Weill Cornell Medicine, the BAND Foundation, the Pediatric Epilepsy Research Foundation, the Epilepsy Foundation, Clara Inspired, the Orphan Disease Center, and the Morris and Alma Schapiro Fund. Z.M.G. has received payment for consultation from Alpha Insights and BioPharm Solutions (South Korea). A.T.B. has received support from and/or has served as a paid consultant for the Epilepsy Foundation, Pediatric Epilepsy Learning Healthcare System, Epilog, UCB, and the Epilepsy Study Consortium. A.D.P. has received research funding from PERF, NIH, Stoke, and Encoded. He performs webinar development for Medscape and Neurology Live. N.S.A. has received research support from NIH, PCORI, EFA, Pfizer, and UCB. He receives royalty payments from Demos. R.A.S. is a consultant for the Epilepsy Study Consortium and receives royalties from UpToDate for authorship of topics related to neonatal seizures. She serves as an associate editor for *Neurology*. None of the other authors has any conflict of interest to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

ORCID

Zachary M. Grinspan  <https://orcid.org/0000-0001-6705-0932>

Anup D. Patel  <https://orcid.org/0000-0001-9313-1541>

Renée A. Shellhaas  <https://orcid.org/0000-0002-3175-3908>


Anne T. Berg  <https://orcid.org/0000-0002-0298-5523>

William D. Gaillard  <https://orcid.org/0000-0001-5709-0033>

Sookyong Koh  <https://orcid.org/0000-0002-2717-6888>

Elissa G. Yozawitz  <https://orcid.org/0000-0001-8230-8364>

Nicholas S. Abend  <https://orcid.org/0000-0001-6166-2663>

Mark P. Fitzgerald  <https://orcid.org/0000-0002-7121-0705>

Jeffrey Buchhalter  <https://orcid.org/0000-0002-6807-8328>

REFERENCES

- Institute of Medicine (US) Roundtable on Evidence-Based Medicine, Olsen L, Aisner D, McGinnis JM, eds. *The Learning Healthcare System: Workshop Summary*. Washington, DC: National Academies Press; 2007.
- Loring DW, Lowenstein DH, Barbaro NM, Fureman BE, Odenkirchen J, Jacobs MP, et al. Common data elements in epilepsy research: development and implementation of the NINDS epilepsy CDE project. *Epilepsia*. 2011;52(6):1186–91.
- Perry MS. Meaningful results in a Jiffy—a PERC of multicenter collaborations. *Epilepsy Curr*. 2016;16(5):299–301.
- Berg AT, Coryell J, Saneto RP, Grinspan ZM, Alexander JJ, Kekis M, et al. Early-life epilepsies and the emerging role of genetic testing. *JAMA Pediatr*. 2017;171(9):863–71.
- Knupp KG, Coryell J, Nickels KC, Ryan N, Leister E, Loddenkemper T, et al. Response to treatment in a prospective national infantile spasms cohort. *Ann Neurol*. 2016;79(3):475–84.
- Shellhaas RA, Wusthoff CJ, Tsuchida TN, Glass HC, Chu CJ, Massey SL, et al. Profile of neonatal epilepsies: characteristics of a prospective US cohort. *Neurology*. 2017;89(9):893–9.
- Gainza-Lein M, Sanchez Fernandez I, Jackson M, Abend NS, Arya R, Brenton JN, et al. Association of time to treatment with short-term outcomes for pediatric patients with refractory convulsive status epilepticus. *JAMA Neurol*. 2018;75(4):410–8.
- Patel AD, Baca C, Franklin G, Herman ST, Hughes I, Meunier L, et al. Quality improvement in neurology: epilepsy Quality Measurement Set 2017 update. *Neurology*. 2018;91(18):829–36.
- Patel AD, Berg AT, Billingham L, Fain D, Fecske E, Feyma T, et al. Quality improvement in neurology: child neurology quality measure set: executive summary. *Neurology*. 2018;90(2):67–73.
- Weathers AL, Haq IU, Ficker DM, Ney JP, Meyers SL. Neurology steering board effects change for a major electronic health record vendor. *Neurol Clin Pract*. 2019;9(4):360–4.
- Boyatzis RE. *Transforming Qualitative Information: Thematic Analysis and Code Development*. Thousand Oaks, CA: Sage Publications; 1998.
- Partnership for Health IT Patient Safety. *Health IT safe practices: toolkit for the safe use of copy and paste*. ECRI Institute website. Published February 2016. Available at: https://www.ecri.org/Resources/HIT/CP_Toolkit/Toolkit_CopyPaste_final.pdf. Accessed January 21, 2020.
- Cramer JA, French J. Quantitative assessment of seizure severity for clinical trials: a review of approaches to seizure components. *Epilepsia*. 2001;42(1):119–29.
- Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology. *Epilepsia*. 2017;58(4):522–30.
- Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. *Epilepsia*. 2017;58(4):512–21.
- Saitwal H, Feng X, Walji M, Patel V, Zhang J. Assessing performance of an electronic health record (EHR) using cognitive task analysis. *Int J Med Informatics*. 2010;79(7):501–6.
- Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, et al. ILAE official report: A practical clinical definition of epilepsy. *Epilepsia*. 2014;55(4):475–82.
- Harden C, Tomson T, Gloss D, Buchhalter J, Cross JH, Donner E, et al. Practice guideline summary: Sudden unexpected death in epilepsy incidence rates and risk factors: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. *Neurology*. 2017;88(17):1674–80.
- Wirrell EC, Laux L, Donner E, Jette N, Knupp K, Meskis MA, et al. Optimizing the diagnosis and management of Dravet syndrome: recommendations from a North American consensus panel. *Pediatr Neurol*. 2017;68(18–34):e13.
- Blachut B, Hoppe C, Surges R, Stahl J, Elger CE, Helmstaedter C. Counting seizures: the primary outcome measure in epileptology from the patients' perspective. *Seizure*. 2015;29:97–103.
- Hoppe C, Poepel A, Elger CE. Epilepsy: accuracy of patient seizure counts. *Arch Neurol*. 2007;64(11):1595–9.
- Knupp KG, Leister E, Coryell J, Nickels KC, Ryan N, Juarez-Colunga E, et al. Response to second treatment after initial failed treatment in a multicenter prospective infantile spasms cohort. *Epilepsia*. 2016;57(11):1834–42.
- Shinnar S, Maytal J, Krasnoff L, Moshe SL. Recurrent status epilepticus in children. *Ann Neurol*. 1992;31(6):598–604.
- Prasad M, Krishnan PR, Sequeira R, Al-Roomi K. Anticonvulsant therapy for status epilepticus. *Cochrane Database Syst Rev*. 2014;(9):CD003723.
- Shah P, Storey M, Axeen ET, Patel AD, Shellhaas RA, Grinspan ZM, et al. Pediatric Epilepsy Learning Healthcare System Quality of Life Questions (PELHS-QOL-2), a novel QOL instrument for use in clinical care. Conference abstract. American Epilepsy Society Annual Meeting (AES) 2019; December 6–10, 2019; Baltimore, MD.
- Goodwin SW, Lambrinos AI, Ferro MA, Sabaz M, Speechley KN. Development and assessment of a shortened Quality of Life in Childhood Epilepsy Questionnaire (QOLCE-55). *Epilepsia*. 2015;56(6):864–72.
- Morita DA, Glauser TA, Modi AC. Development and validation of the Pediatric Epilepsy Side Effects Questionnaire. *Neurology*. 2012;79(12):1252–8.
- Coryell J, Gaillard WD, Shellhaas RA, Grinspan ZM, Wirrell EC, Knupp KG, et al. Neuroimaging of early life epilepsy. *Pediatrics*. 2018;142:3.
- Lindy AS, Stosser MB, Butler E, Downtain-Pickersgill C, Shanmugham A, Retterer K, et al. Diagnostic outcomes for genetic testing of 70 genes in 8565 patients with epilepsy and neurodevelopmental disorders. *Epilepsia*. 2018;59(5):1062–71.
- Ramachandran Nair R, Jack SM, Strohm S. SUDEP: to discuss or not? Recommendations from bereaved relatives. *Epilepsy Behav*. 2016;56:20–5.
- Berg AT, Goldman S. Getting serious about the early-life epilepsies: lessons from the world of pediatric oncology. *Neurology*. 2018;90(18):842–8.
- Egberg MD, Kappelman MD, Gulati AS. Improving care in pediatric inflammatory bowel disease. *Gastroenterol Clin North Am*. 2018;47(4):909–19.
- Anderson JB, Beekman RH 3rd, Kugler JD, Rosenthal GL, Jenkins KJ, Klitzner TS, et al. Improvement in interstage survival in a national pediatric cardiology learning network. *Circ Cardiovasc Qual Outcomes*. 2015;8(4):428–36.
- Barry MJ, Edgman-Levitan S. Shared decision making—pinnacle of patient-centered care. *N Engl J Med*. 2012;366(9):780–1.

35. Billingham V. Through the patient's eyes. Salzburg Global Seminar. Session 356, 1998, as cited in Barry MJ, Edgman-Levitan S, Shared-decision making – the pinnacle of patient-centered care. *N Engl J Med*. 2012;366:780–81.
36. Mbwana JS, Grinspan ZM, Bailey R, Berl M, Buchhalter J, Bumbut A, et al. Using EHRs to advance epilepsy care. *Neurol Clin Pract*. 2019;9(1):83–8.
37. McQuaid L, Breen P, Grimson J, Normand C, Dunne M, Delanty N, et al. Socio-technical considerations in epilepsy electronic patient record implementation. *Int J Med Informatics*. 2010;79(5):349–60.
38. Fitzsimons M, Dunleavy B, O'Byrne P, Dunne M, Grimson J, Kalra D, et al. Assessing the quality of epilepsy care with an electronic patient record. *Seizure*. 2013;22(8):604–10.
39. Delanty N, White M, Benson K, McCormack M, Heavin S, Comerford E, et al. Development of a genomics module within an epilepsy-specific electronic health record: toward genomic medicine in epilepsy care. *Epilepsia*. 2019;60(8):1670–7.
40. Narayanan J, Dobrin S, Choi J, Rubin S, Pham A, Patel V, et al. Structured clinical documentation in the electronic medical record to improve quality and to support practice-based research in epilepsy. *Epilepsia*. 2017;58(1):68–76.
41. Cohen GR, Friedman CP, Ryan AM, Richardson CR, Adler-Milstein J. Variation in physicians' electronic health record documentation and potential patient harm from that variation. *J Gen Intern Med*. 2019;34(11):2355–67.
42. Bruland P, McGilchrist M, Zapletal E, Acosta D, Proeve J, Askin S, et al. Common data elements for secondary use of electronic health record data for clinical trial execution and serious adverse event reporting. *BMC Med Res Methodol*. 2016;16(1):159.
43. Zaharias G. What is narrative-based medicine? Narrative-based medicine 1. *Can Fam Physician*. 2018;64(3):176–80.
44. Joukes E, Abu-Hanna A, Cornet R, de Keizer NF. Time spent on dedicated patient care and documentation tasks before and after the introduction of a structured and standardized electronic health record. *Appl Clin Inform*. 2018;9(1):46–53.
45. Gardner RL, Cooper E, Haskell J, Harris DA, Poplau S, Kroth PJ, et al. Physician stress and burnout: the impact of health information technology. *J Am Med Inform Assoc*. 2019;26(2):106–14.
46. Hafeez B, Paolicchi J, Pon S, Howell JD, Grinspan ZM. Feasibility of automatic extraction of electronic health data to evaluate a status epilepticus clinical protocol. *J Child Neurol*. 2016;31(6):709–16.
47. Goldenholz DM, Moss R, Jost DA, Crone NE, Krauss G, Picard R, et al. Common data elements for epilepsy mobile health systems. *Epilepsia*. 2018;59(5):1020–6.
48. Ancker JS, Kern LM, Abramson E, Kaushal R. The Triangle Model for evaluating the effect of health information technology on healthcare quality and safety. *J Am Med Inform Assoc*. 2012;19(1):61–5.
49. Helbig I, Riggs ER, Barry CA, Klein KM, Dymont D, Thaxton C, et al. The ClinGen Epilepsy Gene Curation Expert Panel—bridging the divide between clinical domain knowledge and formal gene curation criteria. *Hum Mutat*. 2018;39(11):1476–84.
50. Berg AT, Berkovic SF, Brodie MJ, Buchhalter J, Cross JH, van Emde Boas W, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. *Epilepsia*. 2010;51(4):676–85.
51. Luders H, Akamatsu N, Amina S, Baumgartner C, Benbadis S, Bermeo-Ovalle A, et al. Critique of the 2017 epileptic seizure and epilepsy classifications. *Epilepsia*. 2019;60(6):1032–9.
52. Perucca P, Carter J, Vahle V, Gilliam FG. Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy. *Neurology*. 2009;72(14):1223–9.
53. Berg AT. Risk of recurrence after a first unprovoked seizure. *Epilepsia*. 2008;49(Suppl 1):13–8.
54. Devinsky O, Cross JH, Wright S. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. *N Engl J Med*. 2017;377:699–700.
55. Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, et al. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. *N Engl J Med*. 2018;378:1888–97.
56. Berg AT, Rychlik K, Levy SR, Testa FM. Complete remission of childhood-onset epilepsy: stability and prediction over two decades. *Brain*. 2014;137:3213–22.
57. Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. *N Engl J Med*. 2010;362:790–9.
58. O'Callaghan FJ, Edwards SW, Alber FD, Hancock E, Johnson AL, Kennedy CR, et al. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. *Lancet Neurol*. 2017;16:33–42.
59. Hussain SA, Shinnar S, Kwong G, Lerner JT, Matsumoto JH, Wu JY, et al. Treatment of infantile spasms with very high dose prednisolone before high dose adrenocorticotrophic hormone. *Epilepsia*. 2014;55:103–7.
60. Fountain NB, Van Ness PC, Bennett A, Absher J, Patel AD, Sheth KN, et al. Quality improvement in neurology: epilepsy update quality measurement set. *Neurology*. 2015;84:1483–7.
61. Ramachandran Nair R, Jack SM. SUDEP: what do adult patients want to know? *Epilepsy Behav*. 2016;64:195–9.
62. Ho NT, Kroner B, Grinspan Z, Fureman B, Farrell K, Zhang J, et al. Comorbidities of rare epilepsies: results from the rare epilepsy network. *J Pediatr*. 2018;203(249–258):e245.
63. Goodwin SW, Ferro MA, Speechley KN. Development and assessment of the Quality of Life in Childhood Epilepsy Questionnaire (QOLCE-16). *Epilepsia*. 2018;59:668–78.
64. O'Callaghan FJK, Edwards SW, Alber FD, Cortina Borja M, Hancock E, Johnson AL, et al. Vigabatrin with hormonal treatment versus hormonal treatment alone (ICISS) for infantile spasms: 18-month outcomes of an open-label, randomised controlled trial. *Lancet Child Adolesc Health*. 2018;2:715–25.
65. Jain SV, Kothare SV. Sleep and epilepsy. *Semin Pediatr Neurol*. 2015;22:86–92.
66. Grinspan ZM, Shapiro JS, Abramson EL, Hooker G, Kaushal R, Kern LM. Predicting frequent ED use by people with epilepsy with health information exchange data. *Neurology*. 2015;85(12):1031–8.
67. Keros S, Buraniqi E, Alex B, Antonetty A, Fialho H, Hafeez B, et al. Increasing ketamine use for refractory status epilepticus in US pediatric hospitals. *J Child Neurol*. 2017;32:638–46.
68. Moura LM, Schwamm E, Moura Junior V, Seitz MP, Hsu J, Cole AJ, et al. Feasibility of the collection of patient-reported outcomes in an ambulatory neurology clinic. *Neurology*. 2016;87:2435–42.
69. Modi AC, Rausch JR, Glauser TA. Patterns of nonadherence to antiepileptic drug therapy in children with newly diagnosed epilepsy. *JAMA*. 2011;305:1669–76.
70. Berg AT, Zelko FA, Levy SR, Testa FM. Age at onset of epilepsy, pharmacoresistance, and cognitive outcomes: a prospective cohort study. *Neurology*. 2012;79:1384–91.

71. Wirrell EC, Camfield CS, Camfield PR, Dooley JM, Gordon KE, Smith B. Long-term psychosocial outcome in typical absence epilepsy. Sometimes a wolf in sheep's clothing. *Arch Pediatr Adolesc Med.* 1997;151:152–8.
72. Spindler UP, Hotopp LC, Bach VA, Hornemann F, Syrbe S, Andreas A, et al. Seizure disorders and developmental disorders: impact on life of affected families—a structured interview. *Eur J Pediatr.* 2017;176:1121–9.
73. Begley C, Shegog R, Liu H, Tatsuoka C, Spruill TM, Friedman D, et al. Correlates of epilepsy self-management in MEW Network participants: from the Centers for Disease Control and Prevention Managing Epilepsy Well Network. *Epilepsy Behav.* 2018;85:243–7.
74. Nababout R, Andrade DM, Bahi-Buisson N, Cross H, Desquerre I, Dulac O, et al. Outcome of childhood-onset epilepsy from adolescence to adulthood: transition issues. *Epilepsy Behav.* 2017;69:161–9.
75. Bisgaier J, Rhodes KV. Auditing access to specialty care for children with public insurance. *N Engl J Med.* 2011;364:2324–33.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Grinspan ZM, Patel AD, Shellhaas RA, et al. Design and implementation of electronic health record common data elements for pediatric epilepsy: Foundations for a learning health care system. *Epilepsia.* 2021;62:198–216. <https://doi.org/10.1111/epi.16733>

APPENDIX 1

PARTICIPANTS AND CONTRIBUTORS DISCUSSION GROUP PARTICIPANTS

- Amy Bennett, JD. American Academy of Neurology. Minneapolis, MN
- Jeffrey Buchhalter, MD, PhD. Phoenix, AZ
- Jason Coryell, MD, MS. Oregon Health Sciences University. Portland, OR
- Brandy Fureman, PhD. Epilepsy Foundation. Landover, MD
- William Gaillard, MD. Children's National Medical Center. Washington, DC
- Howard Goodkin, MD, PhD. University of Virginia. Charlottesville, VA
- Zachary Grinspan, MD, MS. Weill Cornell Medicine. New York, NY
- Shaun Hussain, MD. University of California, Los Angeles. Los Angeles, CA
- Dennis J. Dlugos, MD. Children's Hospital of Philadelphia. Philadelphia, PA
- Anna Jeong, MD. Lurie Children's Hospital. Chicago, IL
- Sookyoung Koh, MD, PhD. Children's Hospital of Atlanta. Atlanta, GA

- Alison Kukla, MPH. Person with epilepsy. Norfolk, VA
- Matthew Lallas, MD. Children's Hospital of Los Angeles. Los Angeles, CA
- Tobias Loddenkemper, MD. Boston Children's Hospital. Boston, MA
- Juma Mbwana, MD. Children's National Medical Center. Washington, DC
- Tiffani McDonough, MD. Lurie Children's Hospital. Chicago, IL
- Patricia McGoldrick, NP, MPA, MSN. Mount Sinai School of Medicine. New York, NY
- Diego Morita, MD. Cincinnati Children's Hospital. Cincinnati, OH
- Lindsey Morgan, MD. Seattle Children's Hospital. Seattle, WA
- Anup Patel, MD. Nationwide Children's Hospital. Columbus, OH
- Renée Shellhaas, MD, MS. Michigan Medicine. Ann Arbor, MI
- Nilika Singhal, MD. University of California, San Francisco. San Francisco, CA
- Margaret Storey, PhD. Parent of a child with epilepsy. Chicago, IL
- Anne T. Berg, PhD. Lurie Children's Hospital. Chicago, IL
- Steven Wolf, MD. Mount Sinai School of Medicine. New York, NY
- Elissa Yozawitz, MD. Montefiore Medical Center. Bronx, NY

ADDITIONAL CONTRIBUTORS AND ACKNOWLEDGMENTS

American Academy of Neurology Clinical Practice and Quality Staff

Gardiner Lapham, RN, MPH. BAND Foundation

Sarah Huenke. American Academy of Pediatrics

ELECTRONIC HEALTH RECORD ADVISORS

J. Travis Gossey, MD. Weill Cornell Medicine

Lisa Jones, RN. Cerner Corporation

Payton DePalma. Epic Corporation

Greg Strodman. Epic Corporation

Stephanie Idell. Dell Children's Hospital

Stephanie Ingle. Epic Corporation

Khair Lambaz. Epic Corporation

USER GROUP, CHILDREN'S HOSPITAL OF PHILADELPHIA

Pamela P. McDonnell, MD

Ethan M. Goldberg, MD, PhD

Colin Ellis, MD

Xilma Ortiz-Gonzalez, MD, PhD

Sudha K. Kessler, MD

France W. Fung, MD

Lawrence E. Fried, MD

Ryan E. Gill, MD

Robert Stowe, MD

Marissa P. DiGiovine, MD
 Naomi Lewin, MD, PhD
 Lila Worden, MD
 Stacy D. Elkhatib Smidt, MD
 Alyssa R. Rosen, MD
 Amisha B. Patel, MD, MPH
 Eric D. Marsh, MD, PhD

APPENDIX 2 FULL COMMON DATA ELEMENT SPECIFICATIONS

SECTION 1. DIAGNOSIS

[guidance text] ILAE 2014: Epilepsy means (1) at least two unprovoked (or reflex) seizures occurring greater than 24 hours apart OR (2) unprovoked (or reflex) seizure and probability of further seizures similar to the general recurrence risk (at least 60%) after two unprovoked seizures, occurring over the next 10 years or (3) diagnosis of an epilepsy syndrome

[question] Has epilepsy

[answer choices (select one) – copies forward]

Yes

No/uncertain

SECTION 2. SEIZURE FREQUENCY

[question] Last GENERALIZED TONIC-CLONIC SEIZURE (including clonic-tonic-clonic, myoclonic-tonic-clonic, and focal onset seizures with secondary generalization)

[answer choices (select one)]

Never/does not have this seizure type

Today

1-6 days ago (up to 1 week)

1-4 weeks ago (up to 1 month)

5-12 weeks ago (1-3 months)

13-26 weeks ago (3-6 months)

6-12 months ago

13-24 months ago

More than 2 years ago

Uncertain

[logic]—The following two questions only appear if the last generalized tonic-clonic seizure occurred within the past 6 months]

[question] Recently, what is the frequency of GENERALIZED TONIC-CLONIC Seizures?

[answer choices (select one)]

Too many to count

Multiple per day

Daily

Weekly but not daily

Monthly but not weekly

At least once per year but not every month

Less than once per year

Uncertain

Frequency not well defined

[question] In the past 12 months, have any generalized tonic-clonic seizures occurred AT NIGHT or FROM SLEEP?

[answer choices (select one)]

Some at night or from sleep

None at night or from sleep

Unsure if ever at night or from sleep

[question] Last MOTOR Seizure (not including GTCs; eg, myoclonic jerks, drop attacks, tonic seizures, focal motor seizures that do not generalize, or epileptic spasms in patients older than 2 years)

[answer choices (select one)]

Never/does not have this seizure type

Today

1-6 days ago (up to 1 week)

1-4 weeks ago (up to 1 month)

5-12 weeks ago (1-3 months)

13-26 weeks ago (3-6 months)

6-12 months ago

13-24 months ago

More than 2 years ago

Uncertain

[logic]—The following question only appears if the last motor seizure occurred within the past 6 months]

[question] Recently, what is the frequency of MOTOR seizures (not including GTCs)?

[answer choices (select one)]

Too many to count

Multiple per day

Daily

Weekly but not daily

Monthly but not weekly

At least once per year but not every month

Less than once per year

Uncertain

Frequency not well defined

[question] Last NONMOTOR seizure (for example, absence seizure, or seizure with impaired awareness only)

[answer choices (select one)]

Never/does not have this seizure type

Today

1-6 days ago (up to 1 week)

1-4 weeks ago (up to 1 month)

5-12 weeks ago (1-3 months)

13-26 weeks ago (3-6 months)

6-12 months ago

13-24 months ago

More than 2 years ago

Uncertain

[logic]—The following question only appears if the last non-motor seizure occurred within the past 6 months]

[question] Recently, what is the frequency of NONMOTOR seizures?

[answer choices (select one)]

Too many to count

Multiple per day

Daily

Weekly but not daily

Monthly but not weekly

At least once per year but not every month

Less than once per year

Uncertain

Frequency not well defined

[logic—The following question only appears if the child's age is younger than 3 years]

[question] Last EPILEPTIC SPASM (single spasm or cluster)

[answer choices (select one)]

Never/does not have this seizure type

Today

1-6 days ago (up to 1 week)

7-14 days ago (up to 2 weeks)

At least 2 weeks free of spasms

At least 1 month free of spasms

At least 3 months free of spasms

At least 6 months free of spasms

At least 1 year free of spasms

Uncertain

[question] STATUS EPILEPTICUS requiring an emergency department visit in the past 12 months?

[answer choices (select one)]

Yes

No

Uncertain

SECTION 3. QUALITY OF LIFE

[question] Think about the child's usual routines. How often in the past 2 weeks have SEIZURES significantly changed those routines?

[answer choices (select one)]

Every day

Most days (more than half)

Some days (less than half)

Never

Uncertain/did not ask

[question] Think about the child's usual routines. How often in the past 2 weeks have SEIZURE MEDICATION SIDE EFFECTS significantly changed those routines?

[answer choices (select one)]

Every day

Most days (more than half)

Some days (less than half)

Never

Uncertain/did not ask

SECTION 4. EPILEPSY HISTORY

[question] Epilepsy type (best guess, taking into consideration history and diagnostic findings)

[answer choices (select one)—copies forward]

Focal

Generalized

Both focal and generalized

Unknown

[question] TREATMENT RESISTANT? (ie, seizures continue despite adequate trials of two or more anti-epileptic seizure drugs)

[answer choices (select one)—copies forward]

Yes

No

Uncertain

[question] Epilepsy is NEW ONSET? (ie, the first unprovoked seizure was <6 months ago)

[answer choices (select one)]

Yes

No

Uncertain

[question] Age at first unprovoked seizure

[answer choices (select one)—copies forward]

Neonatal (0-29 days)

Infant (1 m up to 1 y)

1 y

2 y

3 y

4 y

5 y

6 y

7 y

8 y

9 y

10 y

11 y

12 y

13 y

14 y

15 y

16 y

17 y

18 y

Roughly toddler (1-3 y)

Roughly preschool (4-6 y)

Roughly school age (7-12 y)

Roughly adolescent (13-18 y)

Adult (19+)

Unknown/unavailable

[question] Current epilepsy syndrome

[answer choices (select one)—copies forward]

Not a syndrome (nonsyndromic, uncertain, too early to tell)

Neonatal. Ohtahara/early infantile epileptic encephalopathy (EIEE)

Neonatal. Early myoclonic encephalopathy (EME)

Neonatal infantile. Benign neonatal or infantile seizures (familial or nonfamilial)

Infantile. Epilepsy of infancy with migrating focal seizures (EIMFS)

Infantile. Infantile spasms (IS)/West syndrome (WS)

Infantile. Febrile seizures plus (GEFS+)

Infantile. Dravet syndrome (DS)

Childhood. Lennox-Gastaut syndrome (LGS)

Childhood. Doose syndrome (epilepsy with myoclonic-atic seizures [EMAS])

Childhood. Benign occipital epilepsy (Panayiotopoulos or Gastaut)

Childhood. Benign epilepsy with centrotemporal spikes (BECTS)

Childhood. Childhood absence epilepsy (CAE)

Adolescence. Juvenile myoclonic epilepsy (JME)

Adolescence. Juvenile absence epilepsy (JAE)

Other. Electrographic status epilepticus of sleep/continuous spike and waves in sleep/Landau-Kleffner syndrome (ESES/CSWS/LKS)

Other. Progressive myoclonic epilepsy (PME)

[question] Other epilepsy syndrome

[answer choices—copies forward] (free text box)

[question] Specific conditions associated with epilepsy

[answer choices (select one)—copies forward]

None of these conditions applies/uncertain

Aicardi syndrome

Angelman syndrome

Down syndrome

Mowat-Wilson syndrome

Rasmussen syndrome

Rett syndrome

Sturge-Weber syndrome

Tuberous sclerosis

Williams syndrome

Wolf-Hirschhorn syndrome

SECTION 5. EPILEPSY ETIOLOGY

[question] Epilepsy etiology is known?

[answer choices (select one)—copies forward]

Yes

No

[question] Most recent brain imaging study(ies)?

[answer choices (select one)—copies forward]

Not done or unavailable

Normal

Abnormal—unlikely to be related to epilepsy (including incidental findings)

Abnormal—likely to be related to epilepsy

[logic—The following questions only appear if the most recent brain imaging study(ies) was abnormal, likely related to epilepsy]

[question] What does the imaging show (select all that apply)?

[subheadings and answer choices—copies forward; may select more than one]

Malformation of cortical development

Focal cortical dysplasia

Hemimegalencephaly

Hypothalamic hamartoma

Lissencephaly

Band heterotopia

Polymicrogyria

Tuberous sclerosis–related dysplasia

Schizencephaly

Other gray matter heterotopia

Hippocampal abnormalities

Hippocampal malrotation

Hippocampal sclerosis

Other hippocampal abnormalities

Other patterns

Corpus callosum hypoplasia or absence

Holoprosencephaly spectrum

Hydrocephalus (any etiology)

Septo-optic dysplasia spectrum

Vascular malformation

Cerebral angioma

Leptomeningeal angiomatosis (Sturge-Weber)

AV malformation

Acquired injury and/or sequelae

Hypoxic ischemic encephalopathy

Intracranial infection

Periventricular leukomalacia

Intraventricular hemorrhage

Trauma

Solid tumor

Stroke

Postoperative cavity

Other imaging finding (free text)

(Free text box)

[question] Genetic testing

[answer choices (select one)—copies forward]

No genetic testing has been done

Some testing done, but no identified genetic cause (ie, unrelated genetic abnormality, testing pending, VUS, or negative)

There is genetic abnormality that explains the epilepsy (more likely than not)

[logic—The following questions only appear if there is a genetic abnormality that explains the epilepsy]

[question] What is the genetic or chromosomal abnormality?

[subheadings and answer choices—copies forward; may select more than one]

Chromosomal

Trisomy 21

Ring chromosome 14

Ring chromosome 20

CNV

dup15q syndrome

Phelan-McDermid syndrome

1p36 deletion syndrome

MECP2 duplication syndrome

Angelman

Uniparental disomy

Imprinting defect

15q11 microdeletion

Specific genes (in alphabetical order)

ALDH7A1

ALG13

ARX

CACNA1A

CACNA1E

CDH2

CDKL5

CHRNA4

CHRNA7

DEPDC5

DNM1

FOXG1

GABRA1

GABRB3

GABRD

GABRG2

GNAO1

GRIN2A

GRIN2B

KCNQ2

KCNQ3

KCNT1

MECP2

PCDH19

POLG

PRRT2

SCN1A

SCN1B

SCN2A

SCN8A

SLC13A5

SLC2A1 (GLUT1)

STX1B

STXBP1

SYNGAP1

TSC1

TSC2

UBE3A

Other genetic finding (free text)

[question] Is there a metabolic etiology?

[answer choices (select one)—copies forward]

Yes

No (low clinical suspicion or testing is negative)

Uncertain

[question] Is there infectious etiology?

[answer choices (select one)—copies forward]

Yes

No (low clinical suspicion or testing is negative)

Uncertain

[question] Is there autoimmune etiology?

[answer choices (select one)—copies forward]

Yes

No (low clinical suspicion or testing is negative)

Uncertain

SECTION 6. COMORBIDITIES

[question] Is there any DEVELOPMENTAL DELAY?

(Based on clinical impression/history)

[answer choices (select one)—copies forward]

Normal development (no delay)

Mild developmental delay (or uncertain)

Definite delay in one domain (Gross Motor, Language, Social)

Definite delay in two or three domains (Gross Motor, Language, Social)

(Too old for developmental delay diagnosis)

[question] Any of the following selected COMORBIDITIES present? (Based on clinical impression/history)

[answer choices—copies forward; may select more than one]

None of these apply

Psychiatric/behavioral/cognitive

ADD/ADHD

Anxiety

Autism/PDD

Depression

Learning disability

Intellectual disability

Neurologic

Cerebral palsy

Hearing impairment

Migraines

Movement disorder

Sleep disorder

Visual impairment (other than refractive errors)

Head shape

Macrocephaly (>95th percentile)

Microcephaly (<5th percentile)

Other abnormal head shape

Technology dependent

Gastrotomy

Tracheostomy

VP shunt

Wheelchair

SECTION 7. TREATMENT

[question] Other than medications, will any of the following be continued and/or recommended?

[subheadings and answer choices; may select more than one]

Diet

No dietary therapy for epilepsy

Ketogenic diet

Modified Atkins diet

Low glycemic diet

Other dietary therapy

Surgery

Scheduled for neurosurgery conference

Not scheduled for neurosurgery conference

SECTION 8. PROCESS MEASURES

[logic—The following question only appears for children 12 years old or older]

[question] TRANSITION to adult care was discussed at this visit?

[answer choices (select one)]

Discussed transition to adult care

Did not discuss transition to adult care at this visit

[question] Discussed SUDEP at this visit?

[answer choices (select one)]

Discussed SUDEP

Did not discuss SUDEP at this visit

[logic—The following question only appears for children 7 years old or older]

[question] Screened for MENTAL HEALTH COMORBIDITIES at this visit?

[answer choices (select one)]

Screened for mental health comorbidities

Did not screen at this visit

[logic—The following question only appears for female children who are 12 years old or older]

[question] Counseled patient or caregiver about how epilepsy and its treatment may affect CONTRACEPTION and/or PREGNANCY?

[answer choices (select one)]

Counseled about contraception and/or pregnancy at this visit

Did not counsel about contraception and/or pregnancy at this visit

Premenstrual, surgically sterile, reproductive organs absent

[logic—The following question only appears for children who have infantile spasms]

[question] For INFANTILE SPASMS, what treatment was given as FIRST LINE?

[answer choices (select one)]

First-line therapy for infantile spasms included ACTH, oral steroids, or vigabatrin (alone or in combination)

First-line therapy for infantile spasms was not ACTH, oral steroids, or vigabatrin

First-line therapy for infantile spasms unknown

SECTION 9. PEDIATRIC EPILEPSY LONGITUDINAL HISTORY NOTE

[large free text box—copies forward]

Abbreviations: ACTH, adrenocorticotrop hormone; ADD, attention-deficit disorder; ADHD, attention-deficit/hyperactivity disorder; AV, arteriovenous; CNV, copy number variation; GTC, generalized tonic-clonic seizure; ILAE, International League Against Epilepsy; PDD, pervasive developmental disorder; SUDEP, sudden unexpected death in epilepsy.